Surrozen, Inc./DE Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Surrozen, Inc./DE (SRZN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $16.11 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $16.11, a 20.13% increase year-over-year.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $13.41, a 46.40% decline year-over-year.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $25.02, a 869.77% increase year-over-year.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.58.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $13.02, a 30.60% decline from fiscal 2024.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $18.76, a 47.67% decline from fiscal 2023.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $35.85, a 484.83% increase from fiscal 2022.
- Surrozen, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $6.13.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.11 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $16.11 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $13.02 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $13.02 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | $12.41 10-Q · filed 2025-08-08 | |||
| 2025-03-31 | $13.41 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | $18.76 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $24.31 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $24.31 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $25.02 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $35.85 10-K · filed 2024-04-10 | |||
| 2023-09-30 | $2.40 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $2.64 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $2.58 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $6.13 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $6.18 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $5.17 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |